Head-to-head · longevity
NMN vs Resveratrol: Which Is Better for Longevity?
NMN (nicotinamide mononucleotide) and resveratrol are the two most hyped supplements in the longevity world, often marketed together as an anti-aging stack. NMN is an NAD+ precursor meant to restore the cellular fuel that declines with age, while resveratrol is a polyphenol from grapes and red wine promoted as a 'sirtuin activator.' People compare them because both are sold on the promise of slower aging and a longer healthspan. The honest picture is more modest: the human evidence is early for both. The right choice depends on what you actually want to influence and how you weigh unproven longevity claims.
| 🧬 NMN (Nicotinamide Mononucleotide) | 🍇 Resveratrol | |
| Evidence | Preliminary | Mixed |
| Best for | Reliably and dose-dependently raises blood NAD+ levels in humans, the biochemical rationale for its useMay modestly improve walking distance, grip strength, and gait speed in some trials of healthy older or middle-aged adults (preliminary, not consistently replicated)A single small RCT found increased skeletal-muscle insulin sensitivity in prediabetic postmenopausal women, though other metabolic markers did not improve | May modestly improve glycemic control (e.g., small HbA1c reductions) and some lipid markers, mainly in people with type 2 diabetes or metabolic syndrome.Higher doses (>=150 mg/day) may lower systolic blood pressure in some trials, with effects concentrated in diabetic or higher-BMI subgroups.May reduce certain inflammatory and oxidative-stress markers (e.g., CRP) in type 2 diabetes, though evidence quality is low and inconsistent across markers. |
| Typical dose | 250–600 mg once daily by mouth; trials have used up to 900 mg/day. Blood NAD+ and 6-minute walk gains plateaued around 600 mg/day in one dose-ranging trial. | Commonly 150–500 mg/day of trans-resveratrol; research doses range up to ~1,000 mg/day. Doses above 1,000 mg/day raise GI side-effect risk with little added proven benefit. Micronized or formulated products are used to offset poor bioavailability. |
| Cited studies | 12 · 12 verified | 23 · 23 verified |
| Key safety | Short-term oral NMN (up to 900 mg/day for 1-3 months) was well tolerated in trials, with no serious adverse events; mild GI upset is occasionally reported. Long-term safety is unknown, and theoretical concerns exist about whether boosting NAD+ could fuel growth of existing cancers, so people with active or prior malignancy should be cautious and consult a clinician. | Generally well tolerated up to about 1,000 mg/day; higher doses (>=1,000–2,000 mg/day) frequently cause GI effects such as nausea, abdominal pain, flatulence, and diarrhea. Resveratrol inhibits CYP enzymes (notably CYP3A4, which metabolizes roughly half of all medications) and can raise blood levels of statins, calcium-channel blockers, immunosuppressants, and some anxiolytics; it may also potentiate anticoagulant/antiplatelet drugs (e.g., warfarin, aspirin) and increase bleeding risk. |
The bottom line
Neither NMN nor resveratrol has any human trial evidence that it extends lifespan or slows aging, so lead with that: the core longevity promise is unproven for both. On the tiers, NMN is preliminary and resveratrol is mixed. NMN reliably and dose-dependently raises blood NAD+ (its clearest, if only biochemical, effect) and hints at modest gains in walking distance, grip strength, and muscle insulin sensitivity in small trials; typical dosing is 250 to 600 mg once daily, with benefits plateauing around 600 mg/day. Resveratrol's mixed data point mainly to small glycemic and lipid improvements and modest blood-pressure lowering in people with type 2 diabetes or metabolic syndrome, at commonly 150 to 500 mg/day, limited by poor oral bioavailability. Safety differs sharply: NMN is well tolerated short-term (up to 900 mg/day for 1 to 3 months) but has unknown long-term safety and a theoretical concern about fueling existing cancers. Resveratrol inhibits CYP3A4 and can raise levels of statins, immunosuppressants, and blood thinners, has estrogenic activity (avoid in hormone-sensitive conditions), and a high-dose trial was halted for kidney harm. Pick NMN if you want the cleaner tolerability profile and the NAD+ rationale; pick resveratrol only if your target is metabolic markers and you have no drug or hormone-sensitivity conflicts. This is educational, not medical advice.
NMN (Nicotinamide Mononucleotide) vs Resveratrol — common questions
Is NMN or resveratrol better for longevity?
Neither has human evidence for extending lifespan, so 'longevity' benefit is unproven for both. NMN (preliminary) reliably raises NAD+ and shows early hints of physical-function gains; resveratrol (mixed) mainly nudges metabolic markers in people with diabetes. Choose NMN for the NAD+ rationale and cleaner tolerability, or resveratrol if your goal is glucose and lipid markers.
Can you take NMN and resveratrol together?
They are frequently stacked based on the theory that resveratrol activates sirtuins while NMN fuels them, but no human trial shows the combination extends life or beats either alone. Resveratrol's CYP3A4 inhibition and bleeding and hormone-sensitivity cautions still apply. Check with a doctor or pharmacist before combining, especially if you take prescription medications.
What is the main difference between NMN and resveratrol?
NMN is an NAD+ precursor that dependably raises blood NAD+ and is well tolerated short-term, with early hints at physical-function gains but unknown long-term safety. Resveratrol is a polyphenol with poor bioavailability, mixed metabolic data, and notable drug interactions (CYP3A4) plus estrogenic activity. Neither is proven to slow aging in humans.
Full dossiers: NMN (Nicotinamide Mononucleotide) → · Resveratrol → · More comparisons